TRINETRA › Sectors › Healthcare
Ind-Swift Laboratories Limited (INDSWFTLAB) — share price, P/E and fundamentals
Ind-Swift Laboratories Limited (NSE: INDSWFTLAB) closed at ₹368.20 on 30 Oct 2026, +263.3% over one year, against a 52-week range of ₹87.15 – ₹426.60.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹240 cr and net profit of ₹34 cr, a 14.2% net margin; revenue grew 57.5% and profit grew 319.4% year on year.
On four consecutive filed quarters its trailing P/E is 38.3; since 12 Aug 2025 its own P/E has ranged from 3.0 to 60.6 (median 4.7), and today's reading is higher than 71% of those 298 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 9.3%, ROCE 11.9%, debt-to-equity 0.01, Piotroski F-score 5 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 56% of 64 sector peers; PBT margin higher than 53% of 64 sector peers; ROE higher than 23% of 64 sector peers.
Key figures
| Last close | ₹368.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -8.2% / +168.0% / +263.3% |
| 52-week low – high | ₹87.15 – ₹426.60 |
| Market capitalisation | ₹3,202 cr |
| Trailing P/E | 38.3 |
| Price / book | 2.17 |
| EV / EBITDA | 21.1 |
| Earnings yield | 2.6% |
| TTM EPS | ₹9.61 |
| TTM net profit | ₹84 cr |
| Quarter revenue | ₹240 cr |
| Quarter net profit | ₹34 cr |
| Net margin | 14.2% |
| Revenue growth (YoY) | +57.5% |
| Profit growth (YoY) | +319.4% |
| Return on equity | 9.3% |
| ROCE | 11.9% |
| Debt / equity | 0.01 |
| Current ratio | 3.90 |
| Free cash flow | ₹-102 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹21.7 cr |
Against Healthcare peers
| Metric | INDSWFTLAB | Peer median | Percentile |
|---|---|---|---|
| Net margin | 14.23 | 12.89 | 56 |
| PBT margin | 18.04 | 17.68 | 53 |
| ROE | 9.28 | 13.87 | 23 |
| ROCE | 11.85 | 17.26 | 20 |
| Debt / equity | 0.01 | 0.11 | 29 |
| FCF margin | -23.55 | -0.87 | 7 |
| Cash conversion | -0.59 | 1.25 | 2 |
| Trailing P/E | 38.32 | 43.26 | 38 |
Questions
What is the P/E ratio of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited's trailing P/E is 38.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 12 Aug 2025 its P/E has ranged 3.0–60.6.
What were Ind-Swift Laboratories Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Ind-Swift Laboratories Limited reported revenue of ₹240 cr and net profit of ₹34 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Ind-Swift Laboratories Limited's ROE?
Return on equity is 9.3% based on the balance sheet dated 30 Sept 2026.
Does Ind-Swift Laboratories Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 30 Sept 2026.
What is INDSWFTLAB's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, INDSWFTLAB traded between ₹87.15 and ₹426.60.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.